|
 |
ByettaThis page contains recent news articles, when available, and an overview of Byetta but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Nausea, vomiting, and kidney failure are some of the possible side effects from taking diabetes drug Byetta, the FDA said. ... CNN Roche's New Diabetes Drug Works Better Than Byetta - Oct 29, 2009 After 24 weeks of treatment, patients who had been given taspoglutide experienced a bigger decline in their blood sugar than those who had been given Byetta ... Wall Street Journal Takeda Agrees to Buy Rights to Amylin's Obesity Drugs - Nov 2, 2009 Amylin's biggest product is the diabetes drug Byetta, co- marketed with Eli Lilly & Co. The injection had sales of $678.5 million for Amylin last year, ... Bloomberg Novo CEO hopeful on Victoza approval - Nov 11, 2009 O: Quote, Profile, Research, Stock Buzz) rival Byetta treatment in Germany by the end of the year. The delays facing Victoza in the all-important US market ... Reuters FDA: Diabetes drug may cause unexpected side effects - Nov 13, 2009 ..."Healthcare professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," said Dr Amy Egan of the fda's ... Private MD For Big Pharma, Diabetes Means Big Business - Nov 13, 2009 While the twice-daily injectible has been a blessing for the millions of patients who currently take the drug, Byetta came under fire in August 2008 when ... Minyanville.com Byetta increases blood sugar during exericse - Nov 10, 2009 Byetta is a drug which stimulates insulin secretion while suppressing glucagon secretion. It works by stimulating a receptor found on cells of the pancreas. ... Examiner.com Amylin 3Q Loss Narrows Substantially On Cost Cuts, Tops Views - Oct 20, 2009 The biopharmaceutical company, which sells diabetes drug Byetta with Eli Lilly & Co. (LLY), has been reducing costs as it combines some Byetta operations ... Wall Street Journal The Mulligan Law Firm is Investigating Injury Claims: Diabetes Drug Byetta ... - Nov 11, 2009 The Mulligan Law Firm is investigating Byetta® injury claims. On November 2nd the FDA released a MedWatch Safety Alert detailing 78 cases of altered kidney ... PR Web (press release) Amylin, Lilly's Byetta Wins FDA Approval as Standalone Therapy, Without Combo ... - Oct 30, 2009 The agency now says the companies have clearance to market exenatide (Byetta) as a standalone therapy for diabetes, which means doctors won't need to ... Xconomy Drug stocks slip; Ipsen gains for second day - Oct 30, 2009 Y) reported that Phase III clinical data showed taspoglutide worked better than the popular diabetes treatment Byetta, or exenatide, in treating type 2 ... MarketWatch Amylin Pharmaceuticals Inc. Reports Operating Results (10-Q) - Nov 5, 2009 Amylin has developed and gained approval for two first-in-class medicines for diabetes SYMLIN injection and BYETTA injection. ... GuruFocus.com Diabetes Drug Promotes Weight Loss - Oct 23, 2009 Liraglutide belongs to the same class of drugs as the diabetes treatment Byetta, which has also been shown to promote weight loss. ... WebMD Eli Lilly posts 3Q profit ahead of forecasts - Oct 21, 2009 ...other revenue rose 51 percent to $176.5 million, mainly due to royalties from the cancer treatment Erbitux and sales of the diabetes treatment Byetta. ... The Associated Press Stocks Running Early (HGSI, VRTX, DNDN, JWN) - Nov 2, 2009 BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 ... Benzinga Amylin Pharmaceuticals Reports Third Quarter Financial Results - Oct 20, 2009 Quarter Ended September 30, 2009 Net product sales of $192.9 million for the quarter ended September 30, 2009 include $171.1 million for BYETTA® (exenatide) ... Reuters Earnings roundup: Sallie Mae, Cymer - Oct 20, 2009 Inc. said its third-quarter loss narrowed as lower research and development costs offset a decline in sales of the diabetes treatment Byetta. ... The Associated Press Lilly film to premiere on World Diabetes Day - Nov 12, 2009 ...development partner Amylin, the company recently offered an update on its Food and Drug Administration application for the injection Byetta (exenatide). Zenopa Alkermes 'Pops' Back in Gear: Cash Aplenty to Fuel Licensing - Nov 6, 2009 And execs are confident that Byetta LAR, a once-weekly version of exenatide partnered with Amylin Pharmaceuticals Inc. and Eli Lilly and Co., ... Therapeutics Daily (press release) (registration) Was Amylin's Drug Unethically Boosted Down Under? - Oct 28, 2009 Xconomy has an item about a brewing controversy in Australia that revolves around San Diego-based Amylin's diabetes drug Byetta. ... Voice of San Diego Marcial: Is Eli Lilly Ripe for a Rebound? - Nov 10, 2009 ...to $397.2 million; Byetta, a diabetes treatment, up 6%, to $115.8 million; and Alimta, a cancer treatment, which saw sales jump 47%, to $461.9 million. ... BusinessWeek Stocks in the Spotlight Monday - Nov 2, 2009 The deal from which Amylin will get $75 million up front came after the Food and Drug Administration approved Amylin's diabetes drug Byetta for extended use ... Barron's Lilly CEO optimistic despite patent cliff - Nov 9, 2009 Moreover, he said drugs in late-stage trials, including treatments for cancer, and a longer-acting form of its widely used Byetta diabetes drug now awaiting ... Reuters Top Biotech Stocks - HGSI, AMLN, PLX - Stock Price Alert - Nov 2, 2009 The company today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for BYETTA (exenatide) injection. ... TransWorldNews (press release) FDA approved expanded indication for exenatide - Nov 3, 2009 The approval of exenatide (Byetta, Amylin and Eli Lilly and Company) as a monotherapy treatment was based on a clinical study of patients with type 2 ... Endocrine Today US HOT STOCKS: Black & Decker, Avis Budget Group Up After-Hours - Nov 2, 2009 Meanwhile, the FDA late Friday approved extended use for Amylin's Byetta as stand-alone therapy with diet and exercise in patients with type 2 diabetes. ... Wall Street Journal Once weekly diabetes treatment promising in first Phase III trial - Nov 2, 2009 Unlike the two currently approved GLP-1 analogues liraglutide (Victoza) and exenatide (Byetta), which must be given daily, taspoglutide is a weekly ... Healthcare Republic David Mendosa, A Champion Of Diabetes Awareness - Nov 1, 2009 Then, I switched to taking Byetta, using two injections daily. Byetta helped me control my blood glucose level somewhat better. ... A Sweet Life, the source for the healthy diabetic (blog) Amylin Pharmaceuticals, Inc. - SWOT Analysis - Oct 24, 2009 It has two marketed products in its portfolio, namely, Byetta and Symlin, for the treatment of diabetes. Amylin primarily operates in the US and Germany. ... PRMinds (press release) REG-Lilly (Eli) & Co: Lilly Rpts Solid 3Q09; Rev Full-Year 09 EPS Guidance - Oct 21, 2009 ...(numbers do not add due to rounding) Byetta® Lilly reports in collaboration revenue its 50 percent share of Byetta's gross margin in the US, and in product ... Reuters Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare ... - Nov 5, 2009 Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) ... Reuters PicksThatMove.com Announces Investment Opinion On: Human Genome Science Inc ... - Nov 2, 2009 BYETTA has now received approval for use as medication that can be used alone along with recommended diet and exercise to improve glycemic control in adults ... Reuters Diabetes report accused of bias - Oct 26, 2009 ...a group that campaigns against pharmaceutical marketing, the report could be compromised by Eli Lilly's incretin mimetic drug Byetta (exenatide). ... Pharmacy News US HOT STOCKS: Ford, Human Genome, CIT, Encore Acquisition - Nov 2, 2009 Meanwhile, the FDA late Friday approved extended use for Amylin's Byetta as stand-alone therapy with diet and exercise in patients with type 2 diabetes. ... Wall Street Journal Is Your Thyroid Making You Fat? Dr. Kent Holtorf Explains How Thyroid Patients ... - Oct 20, 2009 Find out about reverse T3 and leptin testing, and the use of human chorionic gonadotropin (HCG), diabetes medicines like Byetta, Symlin, and Glucophage ... About - News & Issues (blog) World stock markets news summary (US, UK, Europe, Asia) (November 3, 2009) - Nov 3, 2009 ...s and Amylin Pharmaceuticals' Byetta diabetes drug, US FDA said. But Amylin Senior Vice President Orville Kolterman said there was “no evidence from ... Stock Markets Review Eli Lilly and Company Q3 2009 Earnings Call Transcript - Oct 21, 2009 Last quarter we discussed underlying prescription and share of market trends for Cymbalta, Alimta, Cialis, and Byetta. This quarter we will take a look at ... Seeking Alpha (blog) Antipsychotic Drugs Raise Obesity Risk in Children - Oct 27, 2009 Did you know that Lilly made $ billions last year on diabetic meds, Actos,Humulin and Byetta? Yes! They sell a drug that can cause diabetes and then turn a ... dBTechno Market Wrap-Up for November 2, 2009 - Nov 2, 2009 ...[[AMLN]] – Shares of the biopharmaceutical company rose sharply after it announced that the FDA approved an expanded indication for BYETTA injection. ... Sumfolio.com Branded Diet Plans Cost $60 Billion Yet 400000 Die From Obesity Yearly - Nov 3, 2009 Byetta helps with weight control and the rest have little or no effect. My physicians all had the same prescription; eat low sodium, low glycemic carb meals ... Basil & Spice Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA ... - Nov 6, 2009 Intarcia is currently conducting a 3-month phase 2 study comparing ITCA 650 with twice-daily Byetta® exenatide injections among a larger population of type ... Earthtimes (press release) Monday's biggest gaining and declining stocks - Nov 2, 2009 Amylin Pharmaceuticals AMLN and Eli Lilly: LLY The US Food and Drug Administration cleared an additional use for Byetta injection. ... Middle East North Africa Financial Network Incyte – Life After Debt (Part II) - Oct 19, 2009 In 2002, when Lilly (LLY) licensed Byetta from Amylin (AMLN), it paid a total of $110M in upfront payment and equity investment for 50% of the US rights and ... Seeking Alpha (blog) Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of ... - Oct 19, 2009 Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) ... Reuters Amylin Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ... - Nov 9, 2009 The BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection are the two medicines marketed by the company to treat diabetes. ... PR-Inside.com (Pressemitteilung) Critics question ethics of stepped-up pharma data mining - Oct 26, 2009 ...[Did you know that Lilly made nearly $3 billion last year on diabetic meds, Actos,Humulin and Byetta? Yes! They sell a drug that can cause diabetes and then ... FierceHealthIT Stocks May Start Higher In Anticipation Of Positive Economic Signals - RTTNews ... - Nov 2, 2009 News | PowerRating) are expected to move in reaction to their announcement that the FDA has approved an expanded indication for their BYETTA injection, ... Trading Markets (press release) AMLN, CIT, AAI, CAL, UAUA, BGFV, KOPN, PRGO Popular Stocks - Nov 2, 2009 Meanwhile, the FDA late Friday approved extended use for Amylin's Byetta as stand-alone therapy with diet and exercise in patients with type 2 diabetes. ... Ub News Science Finds Healing in Halloween Horrors - Oct 30, 2009 Byetta (exenatide), a diet drug which in one trial helped overweight people with diabetes shed an average of 11 pounds over three years, was based on the ... Atlanta Journal Constitution Novo Nordisk ups 2009 EBIT outlook after Q3 rise - Oct 29, 2009 ...on its Victoza diabetes drug, a rival to Eli Lilly's (LLY.N: Quote, Profile, Research) Byetta, during the fourth quarter. (Reporting by Copenhagen newsroom) Reuters India Amylin shares tumble on Byetta woes - MarketWatch - Aug 27, 2008 By Val Brickates Kennedy, MarketWatch. BOSTON (MarketWatch) -- Amylin Pharmaceutical shares took a serious hit Wednesday, the day after the biotech group ... MarketWatch Bumbling Over Byetta - Aug 19, 2008 Once again, a decision by the US Food and Drug Administration is having a widespread effect on the business of diabetes treatment. ... Forbes … Is Source of Newest Diabetes Drug; Amylin product Byetta, based on... - Apr 30, 2005 The substance that is the basis for Byetta was discovered in the early ... Byetta is taken by injection twice daily, an hour before breakfast and dinner. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Black Box In Byetta's Future? - Aug 18, 2008 Byetta, a twice-daily injection, was approved in 2005 for the lowering of blood sugar in ... Amylin released positive data from a 52-week study on Byetta ... Forbes Amylin, Lilly: Byetta Cuts Hypoglycemia Risk - Jun 24, 2007 By Robert Steyer. Amylin Pharmaceuticals (AMLN) and Eli Lilly (LLY) said Sunday their injectable drug Byetta achieves the same blood-sugar control as ... TheStreet.com - TheStreet.com (subscription) Amylin Gets Euro OK For Byetta, Shares Fall - Nov 21, 2006 Drugmaker Amylin Pharmaceuticals announced Tuesday it received approval from European health regulators to market diabetes drug Byetta. ... Forbes Investor Concerns Over Amylin's Byetta Seen As Overblown - Jul 24, 2006 Morgan Stanley downplayed investors' fears of a potential link between pancreatic complications and Byetta, the diabetes treatment marketed by Eli Lilly and ... Forbes Amylin, Lilly: Byetta Cuts Hypoglycemia Risk - Jun 23, 2007 The Lilly-Amylin announcement comes three days after Novo Nordisk (NVO - commentary - Cramer's Take) said its experimental drug liraglutide produced ... TheStreet.com - TheStreet.com (subscription) Amylin says Byetta outperformed Januvia in trial - Sep 9, 2008 BOSTON, Sept 9 (Reuters) - Eli Lilly and Co and Amylin Pharmaceuticals Inc said on Tuesday that a trial of their diabetes drug Byetta, which was recently ... Forbes Byetta weight loss doubles for diabetics at 2 years - Jun 10, 2006 NEW YORK (Reuters) — Patients taking the recently launched diabetes drug Byetta lost twice as much weight in years than they did in an initial 30-week study ... USA Today FDA calls for expanded Byetta precautions - Oct 16, 2007 WASHINGTON, Oct. 16 (UPI) -- The US Food and Drug Administration announced it suspects a link between usage of Byetta, a type 2 diabetes drug, ... United Press International Amylin posts solid results for once-weekly Byetta - Jun 10, 2008 SAN FRANCISCO—Amylin Pharmaceuticals Inc. late Monday said that a once-weekly version of its diabetes drug Byetta lowered blood sugar in patients more than ... Boston Globe Byetta Boosts Amylin's Sales | Page 2 of 2 | Pharmaceuticals |... - Oct 18, 2006 Graham said she expects Byetta to receive approval in the European Union next year. Last month, an EU medical advisory committee endorsed the drug. ... TheStreet.com - TheStreet.com (subscription) Amylin May See Q3 Upside On Strong Byetta Sales - Oct 25, 2005 Piper Jaffray maintained an "outperform" rating on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) ahead of the biotechnology company's release of ... Forbes Novo Nordisk diabetes drug tops Byetta in trial - Jun 7, 2008 By Bill Berkrot. NEW YORK (Reuters) - Novo Nordisk's experimental type 2 diabetes drug, liraglutide, was superior in controlling blood sugar in a clinical ... Reuters UK A Ray of Hope for Diabetics - Mar 2, 2006 For diabetics, the weight loss caused by Byetta comes as a welcome contrast ... Some patients say Byetta has reversed the course of a disease that can lead ... New York Times Amylin quarterly loss narrows on Byetta sales - Jul 23, 2007 NEW YORK, July 23 (Reuters) - Amylin Pharmaceuticals Inc(AMLN.O) reported a slightly smaller second-quarter loss on Monday as increased sales of the ... Reuters Amylin Rises on Byetta Sales Data - Nov 17, 2008 By Elizabeth Trotta 11/17/08 - 03:19 PM EST. Amylin Pharmaceuticals' (AMLN Quote) shares rose Monday as investors reacted favorably to an uptick in ... TheStreet.com - TheStreet.com (subscription) Amylin's Byetta Has 30% Value Upside To Street View - Aug 26, 2005 Piper Jaffray said the Street is underestimating the dollar value of Byetta from Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) by 30%. ... Forbes … Superiority in Glucose Control Compared to BYETTA in Head-to-Head ... - Oct 31, 2007 After 30 weeks of treatment, both once-weekly exenatide and BYETTA treatment ... "These data confirm the benefits of BYETTA as an important treatment option ... Free with registration - PR Newswire - AccessMyLibrary.com Amylin seeks to limit Byetta prescriptions. - Jun 14, 2006 Jun. 14--San Diego-based Amylin Pharmaceuticals is suffering from an anxiety that many struggling biotechnology companies would envy. ... Free with registration - San Diego Union - Tribune - AccessMyLibrary.com FDA OKs lizard-derived shot for diabetes - May 2, 2005 The Food and Drug Administration approved Byetta, known chemically as ... When those drugs fail, adding Byetta to them offers patients a new option to try ... USA Today US review of standalone Byetta likely to extend - Dec 8, 2008 NEW YORK, Dec 8 (Reuters) - US regulators will likely extend their review of Amylin Pharmaceuticals (AMLN.O) and Eli Lilly's (LLY.N) diabetes drug Byetta ... Reuters Merck's Januvia, Lilly's Byetta Work No Better Than Older Drugs - Jul 10, 2007 By Michelle Fay Cortez. July 10 (Bloomberg) -- Newer diabetes medicines from makers including Merck & Co. and Eli Lilly & Co. work no better than older, ... Bloomberg Amylin's Byetta Still Has Blockbuster Potential - Aug 1, 2005 Morgan Stanley maintained an "overweight" rating on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) ahead of second-quarter results and said the ... Forbes Amylin jumps 30 pct on Byetta LAR diabetes news - Dec 12, 2008 NEW YORK (Reuters) - Amylin Pharmaceuticals (AMLN.O) shares jumped more than 30 percent on Thursday after the company and its partners said they would seek ... Reuters Diabetic drug Byetta cuts blood sugar, Amylin reports - Dec 7, 2007 By Terri Somers. Amylin Pharmaceuticals said yesterday that a clinical trial showed people with adult-onset diabetes taking only the company's drug Byetta ... San Diego Union - Tribune - San Diego Union Tribune 4 Diabetes Drugs Are Seen Raising Hope and Profit - Jun 22, 2006 The success of Byetta, meanwhile, has caused some doctors to question whether ... Like insulin, Byetta must be injected. But unlike insulin, Byetta causes ... New York Times Amylin Pharma May See Upside On Byetta Strength - Sep 6, 2005 Piper Jaffray reiterated an "outperform" rating and $38 target price on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ), saying it remains confident ... Forbes … Lilly, Amylin, Alkermes say Byetta once weekly more effective than... - Jun 9, 2008 SAN FRANCISCO (Thomson Financial) - Amylin Pharmaceuticals Inc, Eli Lilly and Company, and Alkermes Inc announced Monday that the once-weekly version of ... Forbes Gila Monster Hopes Lift Amylin - Aug 23, 2005 The experimental drug, known as Byetta long-acting release, or Byetta LAR, ... Lilly and Amylin sell Byetta, which was approved by the Food and Drug ... TheStreet.com - TheStreet.com (subscription) Getting Even More Bullish On Byetta - Feb 27, 2006 Piper Jaffray raised the price target on Amylin Pharmaceuticals and said a recent physician survey indicates sales growth for diabetes treatment Byetta may ... Forbes Byetta Breakdown For Amylin - Apr 21, 2008 Despite problems for its competition, Amylin Pharmaceuticals reported a worse than expected loss in the first quarter on a decline in sales for its ... Forbes Reuters Summit-Novo sees advantages vs Byetta LAR - Nov 15, 2007 By Bill Berkrot. NEW YORK, Nov 15 (Reuters) - Novo Nordisk A/S (NOVOb.CO) said on Thursday it believes its experimental type 2 diabetes treatment will be as ... Reuters Amylin's Competitor Concerns For Byetta Seen Unwarranted - Feb 6, 2006 Piper Jaffray said recent investor concerns regarding potential rivals to Amylin Pharmaceuticals' diabetes treatment Byetta were overblown and maintained an ... Forbes Lilly Diabetes Drug Shows a Life-Extending Promise - Aug 5, 2008 Can Byetta, an injectable drug that lowers blood sugar, really help people ... Patients who took Byetta had a much lower chance of dying, about 75 percent ... New York Times Lilly: A Flowering of Diabetes Drugs - Jun 9, 2005 What makes Byetta exciting is that it's what I would call a smart drug. ... We see Byetta as being used prior to getting to insulin. ... BusinessWeek INTERVIEW-Lilly says Byetta LAR won't be filed before 2008 - Sep 14, 2007 By Ben Hirschler. LONDON, Sept 14 (Reuters) - Eli Lilly (LLY.N) aims to give top-line clinical data on its big new diabetes hope Byetta LAR in the fourth ... Reuters Amylin's Byetta Has Long-Term Potential - Oct 28, 2005 Morgan Stanley maintained an "overweight" rating on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) after the diabetes-focused drugmaker announced ... Forbes Amylin shares recover slightly after Byetta deaths - Aug 28, 2008 NEW YORK—Shares of Amylin Pharmaceuticals Inc. staged a slight recovery Thursday after falling sharply the day before, when Amlyin and its partner Eli Lilly ... Boston Globe Amylin's Byetta Sales May Lead To Q1 Upside - Mar 30, 2006 Friedman, Billings, Ramsey raised the price target on Amylin Pharmaceuticals and said prescription trends for diabetes drug Byetta may lead to earnings ... Forbes Eli Lilly rolls out diabetes drug Byetta in Europe - Apr 26, 2007 COPENHAGEN, April 26 (Reuters) - Eli Lilly and Co. (LLY.N) said on Thursday its Byetta type 2 diabetes drug would shortly be launched in Britain after its ... Reuters Byetta, first drug in class, wins approval. - Jun 6, 2005 Byetta, first drug in class, wins approval. INDIANAPOLIS -- People with type 2 diabetes have a new option to help them control their blood sugar in the form ... $9.94 - Chain Drug Review - Alacra Store Lilly bullish on 2008 earnings - Dec 6, 2007 The company said on Thursday that Byetta, sold in partnership with Amylin Pharmaceuticals Inc (AMLN.O), successfully controlled blood sugar levels in a ... Reuters Eli Lilly and Co. to launch marketing campaign for diabetes drug. - Sep 19, 2007 Byetta is a drug for diabetics who do not yet need insulin injections. ... But only a fraction of diabetics can take Byetta, which is for patients who do ... Free with registration - Indianapolis Star - AccessMyLibrary.com BYETTA Shown to Reduce Blood Sugar Levels When Added to Patients … - Nov 15, 2005 SAN DIEGO and INDIANAPOLIS, Nov. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today announced positive results from ... Free with registration - PR Newswire - AccessMyLibrary.com Lilly Sees Higher Earnings on Cymbalta, Byetta Sales - Dec 7, 2006 By Duncan Moore. Dec. 7 (Bloomberg) -- Eli Lilly & Co. projected a 2007 earnings increase that trailed analysts' estimates because the planned purchase of ... Bloomberg Amylin Sinks as US Eyes New Study for Weekly Byetta - Nov 4, 2008 By David Olmos. Nov. 4 (Bloomberg) -- Amylin Pharmaceuticals Inc. fell the most in more than nine years in Nasdaq trading after the company said data for ... Bloomberg Diabetes Drug Byetta Linked to Acute Pancreatitis - Oct 17, 2007 US government plans for a flu pandemic have major gaps in terms of treating and caring for children, says a report released Wednesday by the American ... ABC News New diabetes medicines are coming on the market, and manufacturers … - Jul 14, 2006 One drug, Byetta, developed from the saliva of the Gila monster and ... By helping boost natural insulin production, Byetta keeps some patients from needing ... Pay-Per-View - Newsday - ProQuest Archiver Amylin, Novo Nordisk lead drug stocks lower - MarketWatch - Aug 19, 2008 The agency advised doctors to suspend use of Byetta in any patients suspected of ... Byetta is co-marketed with Eli Lilly & Co. , shares of which were down ... MarketWatch Cost cuts help top drug firms - Apr 22, 2008 Lilly was also hit by disappointing sales of its Byetta diabetes drug, while Novartis and Merck, like much of the industry, are dealing with patent ... Toronto Star Amylin Sales Rise, Loss Widens - Jan 28, 2008 Sales of Byetta, a drug for which Amylin partners with Eli Lilly (LLY ... Use of Byetta by specialists declined in 2007 but stabilized late in year, ... TheStreet.com - TheStreet.com (subscription) Promising Data On Diabetes Treatment Ignites Shares - Aug 22, 2005 Byetta, a drug derived from a compound found in the spit of the Gila monster lizard, was approved earlier this year. It helps patients control their blood ... Forbes FDA rejects Byetta data - Nov 6, 2008 WASHINGTON, Nov. 6 (UPI) -- The US Food and Drug Administration has rejected research data for a long-acting version of the diabetes drug Byetta. ... United Press International Amylin says more primary doctors prescribe Byetta - Jan 7, 2008 LOS ANGELES, Jan 7 (Reuters) - Prescription growth for Amylin Pharmaceuticals Inc's (AMLN.O) diabetes drug, Byetta, slowed in 2007 from a year earlier, ... Reuters Lilly Looks Healthy - Dec 11, 2008 The daily-use Byetta came under fire earlier this year when it became associated with pancreatitis, a condition that is rampant in diabetes patients. ... Forbes California and the West; IN BRIEF / PHARMACEUTICALS; Amylin … - Jun 8, 2006 Bradbury would replace Ginger Graham as chief executive within a year as the company works to boost sales of its Byetta and Symlin diabetes treatments. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Lilly stock rises 2 percent on earnings increase - Jan. 29, 2008 - Jan 29, 2008 This is based on the company's expectations that sales for core products like Cymbalta, the sexual dysfunction drug Cialis and the diabetes drug Byetta will ... CNNMoney.com Novo says significant weight loss from liraglutide - Nov 20, 2007 Industry analysts believe liraglutide will have a clear edge over the version of Byetta already on the market. But the big question is how it will measure ... Reuters Newly Approved First-in-Class Treatment for Type 2 Diabetes Is Now … - Jun 12, 2005 Byetta™ (exenatide) injection is now available for Americans struggling to ... BYETTA can help diabetes patients manage blood sugar while potentially losing ... i-newswire.com Biotech's shares fall after Byetta report - Aug 31, 2008 Potential bad news for a drug that Alkermes Inc. helped develop caused the Cambridge biotech's stock to slip. Alkermes helped develop Exenatide LAR, ... $2.95 - Boston Globe - NewsBank Amylin's Byetta Faces Bigger Obstacles - Jul 28, 2008 Several sell-side analysts believed the LAR's FDA approval would be delayed even prior to the recent pancreatitis hubbub because of insufficient trial size. ... TheStreet.com - TheStreet.com (subscription) Amylin, Lilly Diabetes Drug Helps With Weight Loss - Jun 25, 2007 Byetta was approved by the US Food and Drug Administration in April 2005. ... Byetta is a synthetic hormone that stimulates cells in the pancreas to produce ... Bloomberg Event Brief of Q4 2005 Amylin Pharmaceuticals, Inc. Earnings Conferenc... - Feb 9, 2006 The Co. hadn't mentioned BYETTA yet, it was still using the technical name ... BYETTA is now among the most frequently prescribed diabetes medicines in US ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com New diabetes drug Byetta derived from Gila monster saliva. - Nov. 3,... - Nov 3, 2005 New diabetes drug derived from Gila monster's saliva. Fear of injections could slow sales, analysts. NEW YORK (CNN/Money) - A new diabetes treatment from ... CNNMoney.com Amylin posts wider second-quarter net loss - Jul 22, 2008 Net sales of diabetes drug Byetta, which Amylin co-markets with Eli Lilly and ... Byetta sales were in line with the average analyst estimate of about $178 ... Reuters India Harvard Fish Study Leads Novartis to Diabetes Drugs - Feb 6, 2007 A month's worth of Byetta costs about $209 and Januvia is about $164, ... Byetta lowers blood sugar levels by stimulating the pancreas to produce insulin. ... Bloomberg Amylin Lays Off 340 Workers Over Byetta Sales - Nov 10, 2008 By Ed Silverman // November 10th, 2008 // 8:25 pm. The 25 percent staff reduction, which follows sluggish sales of its flagship Byetta diabetes med, ... Pharmalot Lilly's Byetta Gets New Indication - Jan 3, 2007 Eli Lilly said Wednesday the US Food and Drug Administration approved Byetta for type 2 diabetics who have failed on a thiazolidinedione. ... RedOrbit Lizard saliva that may help to lick diabetes - May 8, 2007 Byetta is a synthetic version of a chemical that helps the Gila monster to survive ... Byetta, developed by Eli Lilly, the American pharmaceuticals group, ... Times Online Diabetics see hope (and weight loss) in new drug | Article from … - Mar 3, 2006 For diabetics, the weight loss caused by Byetta comes as a welcome contrast ... Some patients say Byetta has reversed the course of a disease that can lead ... Pay-Per-View - International Herald Tribune - HighBeam Research Amylin 4th-qtr loss narrows; names Bradbury CEO - Jan 30, 2007 But both figures were shy of Wall Street expectations for revenue of $166.4 million and Byetta sales of $140 million to $145 million. Reuters America Losing the Fight With Type 2 Diabetes - Dec 30, 2008 But Byetta comes with its own concerns. The FDA plans to strengthen its warnings ... "We don't know whether this disease association with Byetta is really ... Washington Post Why Amylin Skipped Some Byetta Numbers - Oct 22, 2008 By Brian Orelli. Disney buys Marvel. David Gardner's top stock jumps 1334%! See what David recommends that you buy NEXT. ... fool.com Monotherapy BYETTA(R) Showed Significant Improvement in Glucose … - Dec 6, 2007 SAN DIEGO and INDIANAPOLIS, Dec. 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced study results from a ... Free with registration - PR Newswire - AccessMyLibrary.com Inside Drugmakers' War on Fat - Mar 6, 2008 Another diabetes drug, Byetta, turned into a blockbuster, ... But Byetta is so tied in to Amylin's near-term prospects that investors hang on every bit of ... BusinessWeek Novo files for US, European liraglutide approval - May 23, 2008 O) Byetta. Although analysts believe the Danish drug will have a clear edge over the version of Byetta already on the market it might face stiffer ... Reuters Amylin shares fall on FDA diabetes trial proposals - Mar 3, 2008 O), a once-weekly version of its popular diabetes drug Byetta, ... Morgan Stanley analyst Steven Harr said the fact that Byetta is already on the market ... Reuters BYETTA(R) Treatment for Three and a Half Years Associated with … - Jun 23, 2007 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study that showed BYETTA(R) (exenatide) ... ots.at 'Lizard Spit' Drug May Help With Weight Loss - Sep 19, 2008 The drug is created synthetically and marketed under the name Byetta and is used ... Dr. Antonia Verso from Banner Health in Phoenix said Byetta helped her ... FOXNews Event Brief of Q1 2007 Amylin Pharmaceuticals, Inc. Earnings Conferenc... - Apr 16, 2007 ...is believed to contribute to the continued growth of BYETTA. 1. BYETTA is now approved for use with the three most commonly prescribed classes of oral ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Weekly jab offers hope for diabetes sufferers - Sep 8, 2008 The new treatment, exenatide once-weekly, is essentially a longer-lasting version of the existing drug exenatide, also known as Byetta. ... Telegraph.co.uk Amylin completes W. Chester purchase - Dec 29, 2005 Amylin has developed and gained approval for two first-in-class medicines for diabetes, Symlin (pramlintide acetate) injection and Byetta (exenatide) ... Bizjournals.com Roche, Ipsen launch pivotal trial of diabetes drug - Jun 10, 2008 O) Byetta, given by injection twice a day. Amylin is also developing a longer-lasting version of its drug that would be given once a week. ... Reuters Monotherapy BYETTA® Showed Significant Improvement In Glucose … - Dec 10, 2007 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced study results from a 24-week study of monotherapy, ... Medical News Today - Medical News Today (press release) Europe Anxious For Cymbalta - Aug 22, 2008 Lilly's diabetes drug Byetta, which it co-markets with Amylin Pharmaceuticals (nasdaq: AMLN - news - people ), was scrutinized earlier this week when the ... Forbes Biotech-Stock Mailbag: Amylin - Aug 22, 2008 Amylin Pharmaceuticals'(AMLN Quote) diabetes drug Byetta appears to have a more ... The Food and Drug Administration is considering strengthening the Byetta ... TheStreet.com - TheStreet.com (subscription) Lilly Deserves a Gilding - Nov 7, 2006 These include the early '07 European market launch of diabetes treatment Byetta. Lilly and Amylin (AMLN - commentary - Cramer's Take) have enjoyed success ... TheStreet.com - TheStreet.com (subscription) Lazy lizard source of diabetes drug - Sep 12, 2007 Noel Field, aged 55, has injected Byetta twice daily for three years as part of phase 3 clinical trials of the drug in Australia. ... The Australian Eli Lilly launches anti-diabetes drug Byetta - Oct 10, 2007 US drug major Eli Lilly has launched its new generation diabetes drug Byetta (exenatide injection) in India. The medicine is meant to improve blood sugar ... Business Standard Baxter builds business as backup drug supplier - Jun 29, 2006 Byetta sales were $68 million in the first quarter, Amylin said, but Wall Street ... Baxter would not say how much it will get from manufacturing Byetta, ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Amylin's Sales Top Estimates - Aug 4, 2005 Werber says competition from a host of other drugs -- now before the Food and Drug Administration or in late-stage clinical trials -- will help depress ... TheStreet.com - TheStreet.com (subscription) Icahn raises his interest in Amylin; stock rallies - Sep 16, 2008 Byetta was launched in 2005 and is given in twice-daily injections. ... The two companies also are developing a once-weekly version of Byetta, ... San Diego Union - Tribune - San Diego Union Tribune Amylin lays off 340 as Byetta flags - Nov 11, 2008 The layoff pain in pharma isn't limited to the big guns. Amylin Pharmaceuticals yesterday cut 340 staffers--some 25 percent of its workforce--to save $100 ... FiercePharma US STOCKS-Market flat as energy tempers auto uncertainty - Dec 11, 2008 O) jumped nearly 18 percent to $10.07 after news that the company would seek approval for a long-acting version of its diabetes drug Byetta by mid-2009. ... Reuters Amylin shares drop to seven-year low - Nov 5, 2008 Exenatide LAR is a long-acting version of Byetta, which must be injected ... Amylin and its Byetta development partner, Eli Lilly, were collaborating on the ... San Diego Union - Tribune - San Diego Union Tribune Type 2 drug from the mouths of monsters - Sep 13, 2007 He has injected Byetta twice daily for three years as part of phase 3 clinical ... Drugs like Byetta work along with the remaining cells, controlling blood ... The Australian Byetta and Its Cousins - Jun 19, 2006 Byetta was the star of the show at the just concluded 66th Scientific Sessions of the American Diabetes Association in Washington. HealthCentral.com made it ... HealthCentral.com Alkermes shares rise on outlook for 2009 profit - Jun 16, 2008 But, the company remains partners with Eli Lilly and Amylin Pharmaceuticals Inc. on Exenatide LAR, a longer-lasting version of the diabetes drug Byetta. ... Boston Globe |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
